Kolaja Carey OConnor 4
4 · Revance Therapeutics, Inc. · Filed Jun 20, 2023
Insider Transaction Report
Form 4
Kolaja Carey OConnor
Director
Transactions
- Exercise/Conversion
Common Stock
2023-06-15$18.12/sh+2,500$45,300→ 19,061 total - Sale
Common Stock
2023-06-15$28.24/sh−2,500$70,600→ 16,561 total - Exercise/Conversion
Stock Option (Right to buy)
2023-06-15−2,500→ 8,256 totalExercise: $18.12Exp: 2032-05-03→ Common Stock (2,500 underlying)
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2023 by Ms. Kolaja.
- [F2]The shares subject to the stock option vested on May 4, 2023.